Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Use of Irvingia Gabonensis (Bush Mango)and Cissus Quadrangularis to Reduce Weight and Blood Lipids

This study has been completed.
Sponsor:
Information provided by:
Gateway Health Alliance
ClinicalTrials.gov Identifier:
NCT00526682
First received: September 6, 2007
Last updated: NA
Last verified: September 2007
History: No changes posted

September 6, 2007
September 6, 2007
January 2007
Not Provided
Weight change [ Time Frame: 10 weeks ]
Same as current
No Changes Posted
Blood lipids Body fat Fasting blood glucose [ Time Frame: 10 weeks ]
Same as current
Not Provided
Not Provided
 
The Use of Irvingia Gabonensis (Bush Mango)and Cissus Quadrangularis to Reduce Weight and Blood Lipids
The Effect of Combining Cissus Quadrangularis and Irvingia Gabonensis on Obesity and Obesity Related Diseases

Hypothesis: Cissus quadrangularis as well as Irvingia gabonensis are used in weight management and related conditions. This study set out to investigate if a combination of the two could have additional benefits to overweight and obese people.

To assess and compare the effects of administration of Cissus quadrangularis (Linn) and a Cissus quadrangularis /Irvingia gabonensis combination on body weight blood pressure, fasting blood glucose, plasma total and LDL cholesterol in 72 overweight and obese subjects.

The study was a 10 week randomized, double-blind, placebo-controlled design, involving 72 obese or overweight participants. Participants were randomly divided into three groups (24 participants/ group):

Group 1 - Placebo; Group 2 - Cissus quadrangularis (CQ); Group 3 - Cissus quadrangularis and Irvingia gabonensis (CQ-IG).

The placebo (250mg) or active formulations ((150 mg CQ and 250 mg CQ-IG) were administered twice daily before meals. Weight as well as fasting blood was taken at baseline, and at 4, 8 and 10 weeks.

No major dietary changes or exercises were suggested during the study.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
  • Obesity
  • Overweight
  • Dyslipidemia
Dietary Supplement: Irvingia/cissus combo
Other Name: Irvingia cissus combo
Active Comparator: 1
Comparison of actives for synergy
Intervention: Dietary Supplement: Irvingia/cissus combo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
72
April 2007
Not Provided

Inclusion Criteria:

  • BMI>26kg/m2

Exclusion Criteria:

  • Diabetics
  • Pregnant and lactating
  • Subjects on any other weight loss program
  • Following any specific low calorie diet
Both
19 Years to 55 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00526682
GHACT010
Yes
Not Provided
Gateway Health Alliance
Not Provided
Principal Investigator: Julius E OBEN, PhD University of Yaounde 1
Gateway Health Alliance
September 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP